問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Hualien Tzu Chi Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間：2023-09-19

李啟誠
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李啟誠

List

38Cases

2020-04-13 - 2024-11-19

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2017-11-01 - 2020-03-19

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting7Sites

Terminated3Sites

白禮源
China Medical University Hospital-Taipei

未分科

2023-05-01 - 2034-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2016-01-01 - 2017-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites

2020-05-31 - 2028-05-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2005-12-01 - 2007-12-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-01-13 - 2023-03-06

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2010-09-30 - 2012-08-31

Phase IV

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-11-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-10-26 - 2019-07-31

Phase II/III

A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy

  • Condition/Disease

    Acute Myeloid Leukemia (AML)

  • Test Drug

    Talacotuzumab

Participate Sites
5Sites

Terminated4Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB